Issued 2026-09-25 at $7.59 · now $7.59 (2026-09-25, +0.0% since)
Based on its own history, a month from the 2026-09-25 close, ARVN has typically landed between $5.61 and $9.83 — a range of −26.1% to +29.5% from the issuance price $7.59.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,987 overlapping 1 month windows · 2018-09-27 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.
The cone is anchored at the 2026-09-25 issuance close ($7.59) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where ARVN has typically landed a month from the 2026-09-25 close of $7.59 — the range is history, not a prediction.
- now $7.59 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $7.37 (-2.8%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $6.54–$8.21
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $5.61–$9.83
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-03-07 | −65.2% | −65.2% | +0.0% |
| 2025-03-10 | −64.7% | −64.7% | +0.0% |
| 2025-03-06 | −63.7% | −63.7% | +1.2% |
| 3 best | |||
| 2020-11-23 | +251.2% | +0.0% | +251.2% |
| 2020-11-30 | +251.0% | +0.0% | +251.0% |
| 2020-11-24 | +245.9% | −1.7% | +245.9% |
1,987 overlapping windows · 2018-09-27 – 2026-09-25 · not cherry-picked
Pending catalysts
- 2027-11-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation (source, as of 2026-08-14)
- 2031-03-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | Saik Andrew | director | Sale | 5,696 @ $8.16 | $46K | −2.9% of holding | −1.0% | not yet — horizon still open | 187,432 | Form 4 · filed same day |
| 2026-06-17 | Cacace Angela M | officer | Sale | 2,576 @ $7.59 | $20K | −1.4% of holding | +4.2% | not yet — horizon still open | 180,390 | Form 4 · filed 1 day after the trade |
| 2026-05-21 | Teel Randy | director | Sale | 2,209 @ $9.04 | $20K | −0.8% of holding | −9.6% | not yet — horizon still open | 285,009 | Form 4 · filed 1 day after the trade |
| 2026-05-11 | Saik Andrew | director | Sale | 11,139 @ $9.94 | $111K | −5.5% of holding | −25.9% | not yet — horizon still open | 193,128 | Form 4 · filed 2 days after the trade |
| 2026-05-11 | Berkowitz Noah | officer | Sale | 11,108 @ $9.94 | $110K | −5.5% of holding | −25.9% | not yet — horizon still open | 191,395 | Form 4 · filed 2 days after the trade |
| 2026-05-11 | Cacace Angela M | officer | Sale | 9,657 @ $9.94 | $96K | −5.0% of holding | −25.9% | not yet — horizon still open | 182,966 | Form 4 · filed 2 days after the trade |
| 2026-05-11 | Teel Randy | director | Sale | 9,657 @ $9.94 | $96K | −3.3% of holding | −25.9% | not yet — horizon still open | 287,218 | Form 4 · filed 2 days after the trade |
| 2026-05-11 | Loomis David K | officer | Sale | 1,919 @ $9.94 | $19K | −4.6% of holding | −25.9% | not yet — horizon still open | 40,193 | Form 4 · filed 2 days after the trade |
| 2026-03-18 | Berkowitz Noah | officer | Sale | 6,435 @ $11.10 | $71K | −3.1% of holding | −6.6% | −39.3% | 202,503 | Form 4 · filed 1 day after the trade |
| 2026-03-06 | Morrison Briggs | director | Purchase | 20,000 @ $13.40 | $268K | +26.3% of holding | −14.7% | −46.1% | 96,021 | Form 4 · filed 3 days after the trade |
| 2026-02-27 | Houston John G | director | Sale | 18,822 @ $13.24 | $249K | −1.6% of holding | −15.7% | −43.6% | 1,133,970 | Form 4 · filed 3 days after the trade |
| 2026-02-27 | Houston John G | director | Sale | 11,787 @ $13.14 | $155K | −1.0% of holding | −15.7% | −43.6% | 1,122,183 | Form 4 · filed 3 days after the trade |
| 2026-02-27 | Houston John G | director | Sale | 4,688 @ $13.24 | $62K | −0.4% of holding | −15.7% | −43.6% | 1,152,792 | Form 4 · filed 3 days after the trade |
| 2026-02-23 | Teel Randy | director | Sale | 3,748 @ $12.16 | $46K | −2.4% of holding | −12.3% | −36.5% | 149,696 | Form 4 · filed 2 days after the trade |
| 2026-02-23 | Cacace Angela M | officer | Sale | 2,571 @ $12.16 | $31K | −1.7% of holding | −12.3% | −36.5% | 147,623 | Form 4 · filed 2 days after the trade |
| 2026-02-23 | Loomis David K | officer | Sale | 1,108 @ $12.16 | $13K | −3.6% of holding | −12.3% | −36.5% | 29,692 | Form 4 · filed 2 days after the trade |
| 2026-02-23 | Teel Randy | director | Sale | 1,038 @ $12.16 | $13K | −0.7% of holding | −12.3% | −36.5% | 153,444 | Form 4 · filed 2 days after the trade |
| 2026-02-23 | Cacace Angela M | officer | Sale | 1,038 @ $12.16 | $13K | −0.7% of holding | −12.3% | −36.5% | 150,194 | Form 4 · filed 2 days after the trade |
| 2026-02-13 | Berkowitz Noah | officer | Sale | 5,685 @ $11.89 | $68K | −3.4% of holding | +4.7% | −35.0% | 163,938 | Form 4 · filed 5 days after the trade |
| 2026-02-13 | Saik Andrew | director | Sale | 5,134 @ $11.89 | $61K | −3.1% of holding | +4.7% | −35.0% | 159,267 | Form 4 · filed 5 days after the trade |
| 2026-02-13 | Cacace Angela M | officer | Sale | 4,592 @ $11.89 | $55K | −2.9% of holding | +4.7% | −35.0% | 151,232 | Form 4 · filed 5 days after the trade |
| 2026-02-13 | Teel Randy | director | Sale | 4,403 @ $11.89 | $52K | −2.8% of holding | +4.7% | −35.0% | 154,482 | Form 4 · filed 5 days after the trade |
| 2026-02-13 | Loomis David K | officer | Sale | 1,016 @ $11.89 | $12K | −3.2% of holding | +4.7% | −35.0% | 30,800 | Form 4 · filed 5 days after the trade |
| 2025-11-07 | Loomis David K | officer | Sale | 230 @ $9.89 | $2K | −0.7% of holding | +21.4% | −20.6% | 31,697 | Form 4 · filed same day |
| 2025-09-22 | Morrison Briggs | director | Purchase | 30,000 @ $7.57 | $227K | +65.2% of holding | +27.6% | +38.1% | 76,021 | Form 4 · filed 2 days after the trade |
| 2025-06-24 | Saik Andrew | director | Sale | 5,700 @ $7.61 | $43K | −3.4% of holding | −2.6% | +45.7% | 164,401 | Form 4 · filed same day |
| 2025-06-17 | Cacace Angela M | officer | Sale | 2,583 @ $7.49 | $19K | −1.6% of holding | −7.1% | +44.8% | 154,248 | Form 4 · filed 1 day after the trade |
| 2025-03-18 | Berkowitz Noah | officer | Sale | 8,658 @ $8.59 | $74K | −7.3% of holding | −3.1% | −27.8% | 110,023 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Houston John G | director | Sale | 26,184 @ $16.75 | $439K | −2.2% of holding | −48.1% | −63.6% | 1,162,634 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Taylor Ian | officer | Sale | 7,356 @ $16.75 | $123K | −4.4% of holding | −48.1% | −63.6% | 160,785 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Houston John G | director | Sale | 5,154 @ $16.55 | $85K | −0.4% of holding | −48.1% | −63.6% | 1,157,480 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Cacace Angela M | officer | Sale | 3,061 @ $16.75 | $51K | −3.0% of holding | −48.1% | −63.6% | 98,377 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Taylor Ian | officer | Sale | 1,664 @ $16.55 | $28K | −1.0% of holding | −48.1% | −63.6% | 159,121 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Loomis David K | officer | Sale | 1,214 @ $16.75 | $20K | −6.0% of holding | −48.1% | −63.6% | 18,863 | Form 4 · filed 1 day after the trade |
| 2025-02-24 | Cacace Angela M | officer | Sale | 1,146 @ $16.55 | $19K | −1.2% of holding | −48.1% | −63.6% | 97,231 | Form 4 · filed 1 day after the trade |
| 2024-11-07 | Loomis David K | officer | Sale | 231 @ $27.69 | $6K | −2.8% of holding | −11.1% | −76.5% | 8,040 | Form 4 · filed 5 days after the trade |
| 2024-02-23 | Houston John G | director | Sale | 5,196 @ $47.05 | $244K | −0.5% of holding | −16.1% | −55.7% | 1,036,681 | Form 4 · filed 4 days after the trade |
| 2024-02-23 | Cassidy Sean A | director | Sale | 1,702 @ $47.05 | $80K | −0.9% of holding | −16.1% | −55.7% | 181,916 | Form 4 · filed 4 days after the trade |
| 2024-02-23 | Taylor Ian | officer | Sale | 1,701 @ $47.05 | $80K | −1.1% of holding | −16.1% | −55.7% | 147,522 | Form 4 · filed 4 days after the trade |
| 2024-02-23 | Peck Ronald | officer | Sale | 1,699 @ $47.05 | $80K | −2.5% of holding | −16.1% | −55.7% | 67,516 | Form 4 · filed 4 days after the trade |
| 2023-11-08 | Loomis David K | officer | Sale | 229 @ $17.05 | $4K | −2.7% of holding | +101.7% | +70.5% | 8,271 | Form 4 · filed 370 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
90 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-24 | Bain Linda | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Cunningham Everett | director | Award / grant | 15,527 | 41,572 | Form 4 |
| 2026-06-24 | Cunningham Everett | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Kennedy Edward Moore Jr. | director | Award / grant | 15,527 | 54,957 | Form 4 |
| 2026-06-24 | Kennedy Edward Moore Jr. | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Morrison Briggs | director | Award / grant | 15,527 | 111,548 | Form 4 |
| 2026-06-24 | Morrison Briggs | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Norwalk Leslie V | director | Award / grant | 15,527 | 41,572 | Form 4 |
| 2026-06-24 | Norwalk Leslie V | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Smaldone Alsup Laurie | director | Award / grant | 15,527 | 41,572 | Form 4 |
| 2026-06-24 | Smaldone Alsup Laurie | director | Award / grant | 22,714 | 22,714 | Form 4 |
| 2026-06-24 | Bain Linda | director | Award / grant | 15,527 | 41,572 | Form 4 |
| 2026-02-26 | Cacace Angela M | officer | Award / grant | 67,000 | 67,000 | Form 4 |
| 2026-02-26 | Cacace Angela M | officer | Award / grant | 45,000 | 192,623 | Form 4 |
| 2026-02-26 | Teel Randy | director | Award / grant | 147,791 | 297,487 | Form 4 |
| 2026-02-26 | Saik Andrew | director | Award / grant | 67,000 | 67,000 | Form 4 |
| 2026-02-26 | Loomis David K | officer | Award / grant | 18,504 | 18,504 | Form 4 |
| 2026-02-26 | Berkowitz Noah | officer | Award / grant | 67,000 | 67,000 | Form 4 |
| 2026-02-26 | Teel Randy | director | Award / grant | 218,691 | 218,691 | Form 4 |
| 2026-02-26 | Berkowitz Noah | officer | Award / grant | 45,000 | 208,938 | Form 4 |
| 2026-02-26 | Loomis David K | officer | Award / grant | 12,420 | 42,112 | Form 4 |
| 2026-02-26 | Saik Andrew | director | Award / grant | 45,000 | 204,267 | Form 4 |
| 2025-06-25 | Bain Linda | director | Award / grant | 16,025 | 26,045 | Form 4 |
| 2025-06-25 | Smaldone Alsup Laurie | director | Award / grant | 16,025 | 26,045 | Form 4 |
| 2025-06-25 | Smaldone Alsup Laurie | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | Bain Linda | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | YOUNG JOHN D | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | Norwalk Leslie V | director | Award / grant | 16,025 | 26,045 | Form 4 |
| 2025-06-25 | Morrison Briggs | director | Award / grant | 16,025 | 46,021 | Form 4 |
| 2025-06-25 | Morrison Briggs | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | YOUNG JOHN D | director | Award / grant | 16,025 | 26,045 | Form 4 |
| 2025-06-25 | Cunningham Everett | director | Award / grant | 16,025 | 26,045 | Form 4 |
| 2025-06-25 | Cunningham Everett | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | Kennedy Edward Moore Jr. | director | Award / grant | 16,025 | 39,430 | Form 4 |
| 2025-06-25 | Kennedy Edward Moore Jr. | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | Norwalk Leslie V | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-06-25 | AGARWAL SUNIL | director | Award / grant | 16,025 | 30,166 | Form 4 |
| 2025-06-25 | AGARWAL SUNIL | director | Award / grant | 23,105 | 23,105 | Form 4 |
| 2025-05-09 | Berkowitz Noah | officer | Award / grant | 59,600 | 169,623 | Form 4 |
| 2025-05-09 | Berkowitz Noah | officer | Award / grant | 91,000 | 91,000 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.